Publications
69
Citations
2,562
Est. group size
~21
Recurring co-author estimate
Active years
16
Publishing since 2011
Emily A. Hemann's research focuses on how the immune system responds to viral and bacterial infections, particularly influenza, SARS-CoV-2, and bacterial infections in cystic fibrosis. Her work examines innate immune sensors (like IFITM3 and interferons), immune cell signaling pathways, and T cell memory development, often using mouse models to understand infection outcomes and inform vaccine design. This research combines molecular immunology with applications to vaccine development and treatment of chronic infections.
Publication output has grown over the past decade, rising from about 2 papers per year around 2017-2018 to a steady 6-9 papers per year since 2020.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Lineage-specific chromatin poising enforced by ETS-IRF composite elements determines the divergent interferon responses of plasmacytoid dendritic cells and epithelial cells
bioRxiv (Cold Spring Harbor Laboratory) · 2026
- Aiolos restricts the generation of antigen-inexperienced, virtual memory CD8+ T cells in mice
Nature Communications · 2025
- Detection of pre-existing immunity to bacterial Cas9 proteins in people with cystic fibrosis
ImmunoHorizons · 2025
- IFITM3-deficient mice as a model for testing influenza virus vaccines via the intramuscular route
Vaccine · 2025
- Aiolos restricts the generation of antigen-inexperienced, virtual memory CD8 <sup>+</sup> T cells
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- Detection of Pre-Existing Immunity to Bacterial Cas9 Proteins in People with Cystic Fibrosis
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- IFITM3 deficient mice as a model for testing influenza virus vaccines
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- Targeting the MEK1/2 pathway to combat <i>Staphylococcus aureus</i> infection and inflammation in cystic fibrosis
mBio · 2025
- Gasdermin D promotes influenza virus-induced mortality through neutrophil amplification of inflammation
Nature Communications · 2024
- MEK1/2 inhibition decreases pro-inflammatory responses in macrophages from people with cystic fibrosis and mitigates severity of illness in experimental murine methicillin-resistant Staphylococcus aureus infection
Frontiers in Cellular and Infection Microbiology · 2024
- Innate immune control of influenza virus interspecies adaptation via IFITM3
Nature Communications · 2024
- IFN-λ uniquely promotes CD8 T cell immunity against SARS-CoV-2 relative to type I IFN
JCI Insight · 2024
- Established and Emerging Roles of <scp>DEAD</scp>/H‐Box Helicases in Regulating Infection and Immunity
Immunological Reviews · 2024
- Exploiting a type III interferon response to improve chemotherapeutic safety and efficacy
European Journal of Pharmaceutical Sciences · 2024
- Exploiting a Type III Interferon Response to Improve Chemotherapeutic Safety and Efficacy
Research Square · 2024
- bioRxiv (Cold Spring Harbor Laboratory)×13
- The Journal of Immunology×12
- Nature Communications×6
- Nature Immunology×2
- Frontiers in Immunology×2
- Dina Bugybayeva
Medicine · The Ohio State University
- Veerupaxagouda Patil
Medicine · The Ohio State University
- Jennifer Schrock
Medicine · The Ohio State University
- Sourabh Soni
Medicine · The Ohio State University
- Samuel Speaks
Immunology and Microbiology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile